How the liver affects the drug mirdametinib
Treatments studied
This study looks at how mirdametinib is processed in people with liver problems compared to healthy people. It will help doctors understand if the dose needs to be adjusted.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 18 and 32, and you weigh more than 110 pounds.
- If you have liver problems, they must be stable and long-lasting (over 6 months).
- You must not have active infections like hepatitis B or C, unless you've been treated and the virus is undetectable.
- You cannot have a history of certain stomach or intestine surgeries that could affect how the drug is absorbed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how probenecid (a medicine for gout) changes the levels of mirdametinib (an experimental cancer drug) in healthy people. It helps doctors understand dosing and safety before testing in patients.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This Phase 1 study measures how tasurgratinib (E7090) and its breakdown product move through the body in people with mild or moderate liver impairment. It aims to understand appropriate dosing and safety considerations for liver impairment.
This research study tests how two experimental drugs (AZD9550 and AZD6234) work in people with different levels of liver function. The goal is to understand whether liver disease changes how the body processes these medications, which may help doctors safely treat patients with liver problems in the future.
This study tests a new drug called sevabertinib to see if it changes how the body handles metformin, a common diabetes medicine. It is for healthy adults and will help researchers understand if the two drugs can be taken together safely.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.